Alzamend Neuro Management
Management criteria checks 1/4
Alzamend Neuro's CEO is Stephan Jackman, appointed in Nov 2018, has a tenure of 5.17 years. total yearly compensation is $2.22M, comprised of 13.5% salary and 86.5% bonuses, including company stock and options. directly owns 0.043% of the company’s shares, worth €2.10K. The average tenure of the management team and the board of directors is 4.7 years and 2.6 years respectively.
Key information
Stephan Jackman
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 13.49% |
| CEO tenure | 5.2yrs |
| CEO ownership | 0.04% |
| Management average tenure | 4.7yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2023 | n/a | n/a | -US$15m |
| Jul 31 2023 | n/a | n/a | -US$15m |
| Apr 30 2023 | US$2m | US$300k | -US$15m |
| Jan 31 2023 | n/a | n/a | -US$15m |
| Oct 31 2022 | n/a | n/a | -US$13m |
| Jul 31 2022 | n/a | n/a | -US$13m |
| Apr 30 2022 | US$473k | US$303k | -US$12m |
| Jan 31 2022 | n/a | n/a | -US$10m |
| Oct 31 2021 | n/a | n/a | -US$8m |
| Jul 31 2021 | n/a | n/a | -US$6m |
| Apr 30 2021 | US$225k | US$225k | -US$5m |
| Jan 31 2021 | n/a | n/a | -US$5m |
| Oct 31 2020 | n/a | n/a | -US$5m |
| Jul 31 2020 | n/a | n/a | -US$5m |
| Apr 30 2020 | US$2m | US$188k | -US$4m |
| Jan 31 2020 | n/a | n/a | -US$4m |
| Oct 31 2019 | n/a | n/a | -US$4m |
| Jul 31 2019 | n/a | n/a | -US$4m |
| Apr 30 2019 | US$3m | US$50k | -US$5m |
Compensation vs Market: Stephan's total compensation ($USD2.22M) is above average for companies of similar size in the German market ($USD407.69K).
Compensation vs Earnings: Stephan's compensation has increased whilst the company is unprofitable.
CEO
Stephan Jackman (46 yo)
5.2yrs
Tenure
US$2,223,611
Compensation
Mr. Stephan Jackman has been Chief Executive Officer of Alzamend Neuro, Inc. since November 20, 2018 and its Director since September 2020. Mr. Jackman has experience in administration, business and produc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.2yrs | US$2.22m | 0.043% € 2.1k | |
| Chief Financial Officer | 2.4yrs | US$116.67k | 0.076% € 3.7k | |
| Founder & Vice Chairman | no data | no data | 2.34% € 115.5k | |
| Executive VP | 4.7yrs | US$50.00k | 0% € 0 | |
| Senior Vice President of Finance | 2.6yrs | no data | 0% € 0 |
4.7yrs
Average Tenure
54yo
Average Age
Experienced Management: 9ZT1's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.3yrs | US$2.22m | 0.043% € 2.1k | |
| Founder & Vice Chairman | no data | no data | 2.34% € 115.5k | |
| Executive VP | 3.3yrs | US$50.00k | 0% € 0 | |
| Chairman of the Board | 7.6yrs | US$50.00k | 0.94% € 46.1k | |
| Independent Director | 2.6yrs | US$25.00k | 0.056% € 2.8k | |
| Independent Director | 2.6yrs | US$25.00k | 0.080% € 3.9k | |
| Member of Scientific Advisory Board | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.6yrs | US$25.00k | 0.094% € 4.6k | |
| Independent Director | 2.6yrs | US$25.00k | 0.094% € 4.6k | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data |
2.6yrs
Average Tenure
55yo
Average Age
Experienced Board: 9ZT1's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/27 00:24 |
| End of Day Share Price | 2023/10/30 00:00 |
| Earnings | 2023/10/31 |
| Annual Earnings | 2023/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alzamend Neuro, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Michael Okunewitch | Maxim Group |